domesticsale.info - Ciprofloxacin Hcl Oral : Uses, Side Effects, Interactions, Pictures

BUY NOW For Sale 70%!
buy viagra

Tannosynt bad dosierung ciprofloxacin

  • 1.

    S. D. Patil, L. Y. Ngo, P. Glue, and J. D. Unadkat. Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter. Pharm. Res. 15:950–952 (1998).PubMedGoogle Scholar

  • 2.

    H. Liedholmand and A. Melander. Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation. Clin. Pharmacol. Ther. 40:29–36 (1986).CrossRefGoogle Scholar

  • 3.

    J. J. Leyden. Absorption of minocycline and tetracycline: effect of food, milk and iron. Int. Congr. Symp. Ser.—R. Soc. Med. 95:87–92 (1985).Google Scholar

  • 4.

    D. Brownand and R. Juhl. Decreased bioavailability of digoxacin due to antacids and kaolin-pectin. N. Engl. J. Med. 19:1034–1037 (1976).CrossRefGoogle Scholar

  • 5.

    J. Dressman. Comparison of canine and human gastrointestinal physiology. Pharm. Res. 3:123–131 (1986).Google Scholar

  • 6.

    T. Kararli. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of human and commonly used laboratory animals. Biopharm. Drug Dispos. 16:351–380 (1995).PubMedGoogle Scholar

  • 7.

    D. Fleisher, C. Li, Y. Zhou, L.-H. Pao, and A. Karim. Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin. Pharmacokinet. 36:233–254 (1999).PubMedGoogle Scholar

  • 8.

    L. Schmidtand and K. Dalhoff. Food-drug interactions. Drugs 62:1481–1502 (2002).Google Scholar

  • 9.

    B. Singh. Effects of food on clinical pharmacokinetics. Clin. Pharmacokinet. 37:213–255 (1999).PubMedGoogle Scholar

  • 10.

    Physician Desk Reference Electronic Library, http://www.thomsonhc.com/pdrel/librarian/ND_PR/Pdr Accessed 11/2004 – 02/2006.

  • 11.

    ACD/PhysChem Batch, version 9.0. Advanced Chemistry Development, Inc. Toronto, Canada.Google Scholar

  • 12.

    The United States Pharmacopeia. Authority of the United States Pharmacopeial Convention, 25th ed. National Publishing, Philadelphia, PA 2004.Google Scholar

  • 13.

    Analytical Profiles of Drug Substances. Series editor: K. Florey. Academic, New York (1972–1991).Google Scholar

  • 14.

    The Merck Index, 13th ed. Merck Research Laboratories, Rahway, NJ (2001).Google Scholar

  • 15.

    USP DI Volume III, Approved Drug Products and Legal Requirements, 26th ed. United States Pharmacopeial Convention, Inc. Rockville, MD (2006).Google Scholar

  • 16.

    D. Oh, R. Curl, and G. Amidon. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm. Res. 10:264–270 (1993).PubMedGoogle Scholar

  • 17.

    W. Curatolo. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Technol. Today 1:387–393 (1998).Google Scholar

  • 18.

    D. Sun, L. X. Yu, M. A. Hussain, D. A. Wall, R. L. Smith, and G. L. Amidon. In vitro testing of drug absorption for drug ‘developability’ assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr. Opin. Drug Discov. Dev. 7:75–85 (2004).Google Scholar

  • 19.

    SAS/STAT® User’s Guide, Version 6, Fourth Edition, Volume 2. Chapter 27, The LOGISTIC procedure, 1071–1126 (1990).Google Scholar

  • 20.

    Y. Li. Mechanisms of region-dependent absorption of a weakly basic hiv protease inhibitor, indinavir: clinical ramifications and comparison with nelfinavir, pH. D thesis, University of Michigan, Ann Arbor, MI (2001).Google Scholar

  • 21.

    N. Petri, C. Tannergren, D. Rungstad, and H. Lennernaes. Transport characteristics of fexofenadine in the Caco-2 Cell Model. Pharm. Res. 21:1398–1404 (2004).PubMedGoogle Scholar

  • 22.

    S. Renand and E. J. Lien. Caco-2 cell permeability vs. human gastro-intestinal absorption: QSAR analysis. Prog. Drug Res. 54:1–23 (2000).Google Scholar

  • 23.

    N. A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernas, A. S. Hussain, H. E. Junginger, S. A. Stavchansky, K. K. Midha, V. P. Shah, and G. L. Amidon. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Molecular Pharmaceutics 1:85–96 (2004).PubMedGoogle Scholar

  • 24.

    A. J. Humberstone, C. J. H. Porter, and N. W. Charman. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J. Pharm. Sci. 85:525–529 (1996).PubMedGoogle Scholar

  • 25.

    C.-Y. Wu and L. Z. Benet. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22:11–23 (2005).PubMedGoogle Scholar

  • 26.

    J. Fraser and P. Gibson. Mechanisms by which food intake elevates circulating levels of hyaluronan in humans. J. Intern. Med. 258:460–466 (2005).PubMedGoogle Scholar

  • 27.

    G. L. Amidon, H. Lennernaes, V. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413–420 (1995).PubMedGoogle Scholar

  • 28.

    E. M. Persson, A.-S. Gustafsson, A. S. Carlsson, R. G. Nilsson, L. Knutson, P. Forsell, G. Hanisch, H. Lennernaes, and B. Abrahamsson. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm. Res. 22:2141–2151 (2005).PubMedGoogle Scholar

  • 29.

    N. Ahuja, A. Singh, and B. Singh. Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. J. Pharm. Pharmacol. 55:859–894 (2003).PubMedGoogle Scholar

  • 30.

    E. Lipka, J. M. Hilfinger, C. A. Siersma, Y. Tsume, J. R. Crison, R. E. Ridgewell, and G. L. Amidon. Evaluation of Imiquimod and analogs with respect to their oral delivery potential. Proc. Int. Symp. Control. Release Bioact. Mater. 24:337–338 (1997).Google Scholar

  • 31.

    I. D. Cockshott, S. D. Oliver, J. J. Young, K. J. Cooper, and D. C. Jones. The effect of food on the pharmacokinetics of the bicalutamide (‘Casodex’) enantiomers. Biopharm. Drug Dispos. 18:499–507 (1997).PubMedGoogle Scholar

  • 32.

    W. N. Charman, M. C. Rogge, A. W. Boddy, and B. M. Berger. Effect of food and a monoglyceride emulsion formulation on danazol bioavailability. J. Clin. Pharmacol. 33:381–386 (1993).PubMedGoogle Scholar

  • 33.

    A. Van Peer, R. Woestenborghs, J. Heykants, R. Gasparini, and G. Gauwenbergh. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur. J. Clin. Pharmacol. 36:423–426 (1989).Google Scholar

  • 34.

    E. Liang, J. Proudfoot, and M. Yazdanian. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers. Pharm. Res. 17:1168–1174 (2000).PubMedGoogle Scholar

  • 35.

    C. Masungi, C. Borremans, B. Willems, J. Mensch, A. van Dijck, P. Augustijns, M. E. Brewster, and M. Noppe. Usefulness of a novel Caco-2 cell perfusion system. I. In vitro prediction of the absorption potential of passively diffused compounds. J. Pharm. Sci. 93:2507–2521 (2004).PubMedGoogle Scholar

  • 36.

    E. K. Hussey, K. H. Donn, J. R. Powell, A. P. Lahey, and G. E. Pakes. Albuterol extended-release products: effect of food on the pharmacokinetics of single oral doses of Volmax and Proventil Repetabs in healthy male volunteers. J. Clin. Pharmacol. 31:561–4 (1991).PubMedGoogle Scholar

  • 37.

    A. Tronde, B. Norden, H. Marchner, A.-K. Wendel, H. Lennernaes, and U. H. Bengtsson. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: Structure-absorption relationships and physicochemical profiling of inhaled drugs. J. Pharm. Sci. 92:1216–1233 (2003).PubMedGoogle Scholar

  • 38.

    J. Fuji, N. Inotsume, and M. Nakano. Effect of food on the bioavailability of bromazepam following oral administration in healthy volunteers. J. Pharmacobio-Dyn. 13:269–271 (1990).Google Scholar

  • 39.

    Z. Kopitar, B. Vrhovac, L. Povsic, F. Plavsic, I. Francetic, and J. Urbancic. The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine. Eur. J. Drug Metab. Pharmacokinet. 16:177–181 (1991).PubMedCrossRefGoogle Scholar

  • 40.

    Y. M. Ponce, M. A. C. Perez, V. R. Zaldivar, M. B. Sanz, D. S. Mota, and F. Torrens. Prediction of intestinal epithelial transport of drug in (Caco-2) cell culture from molecular structure using in silico approaches during early drug discovery. Internet Electronic Journal of Molecular Design 4:124–150 (2005).Google Scholar

  • 41.

    B. Reigner, J. Verweij, L. Dirix, J. Cassidy, C. Twelves, D. Allman, E. Weidekamm, B. Roos, L. Banken, M. Utoh, and B. Osterwalder. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin. Cancer Res. (an official journal of the American Association for Cancer Research) 4:941–948 (1998).Google Scholar

  • 42.

    Bristol-Myers Squibb Internal Database. Bristol-Myers Squibb Co, New York, NY. Accessed 02/2006.Google Scholar

  • 43.

    S. Yamashita, E. Hattori, A. Shimada, Y. Endoh, Y. Yamazaki, M. Kataoka, T. Sakane, and H. Sezaki. New methods to evaluate intestinal drug absorption mediated by oligopeptide transporter tannosynt bad dosierung ciprofloxacin from in vitro study using Caco-2 cells. Drug Metab. Pharmacokinet. 17:408–415 (2002).PubMedGoogle Scholar

  • 44.

    R. M. Menon and W. H. Barr. Comparison of ceftibuten transport across Caco-2 cells and rat jejunum mounted on modified ussing chambers. Biopharm. Drug Dispos. 24:299–308 (2003).PubMedGoogle Scholar

  • 45.

    P. V. Desmond, P. J. Harman, N. Gannoulis, M. Kamm, and M. L. Mashford. The effect of an antacid and food on the absorption of cimetidine and ranitidine. J. Pharm. Pharmacol. 42:352–354 (1990).PubMedGoogle Scholar

  • 46.

    A. Avdeef, P. Artursson, S. Neuhoff, L. Lazorova, J. Grasjoe, and S. Tavelin. Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA pKfluxa method. Eur. J. Pharm. Sci. 24:333–349 (2005).PubMedGoogle Scholar

  • 47.

    A. Shah, M.-C. Liu, D. Vaughan, and A. H. Heller. Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. J. Antimicrob. Chemother. 43:49–54 (1999).PubMedGoogle Scholar

  • 48.

    N. M. Griffiths, B. H. Hirst, and N. L. Simmons. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway? J. Pharmacol. Exp. Ther. 269:496–502 (1994).PubMedGoogle Scholar

  • 49.

    K. Laitinen, A. Patronen, P. Harju, E. Loyttyniemi, L. Pylkkanen, T. Kleimola, and K. Perttunen. Timing of food intake has a marked effect on the bioavailability of clodronate. Bone (New York) 27:293–296 (2000).Google Scholar

  • 50.

    J. Raiman, S. Tormalehto, K. Yritys, H. E. Junginger, and J. Monkkonen. Effects of various absorption enhancers on transport of clodronate through Caco-2 cells. Int. J. Pharm. 261:129–136 (2003).PubMedGoogle Scholar

  • 51.

    C. Lippert, A. Keung, T. Arumugham, M. Eller, W. Hahne, and S. Weir. The effect of food on the bioavailability of dolasetron mesylate tablets. Biopharm. Drug Dispos. 19:17–19 (1998).PubMedGoogle Scholar

  • 52.

    J. Dow, G. F. Di Francesco, and C. Berg. Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog. J. Pharm. Sci. 85:685–689 (1996).PubMedGoogle Scholar

  • 53.

    J. J. Hanyok. Clinical pharmacokinetics of sotalol. Am. J. Cardiol. 72:19A–26A (1993).PubMedGoogle Scholar

  • 54.

    T. D. Bjornsson, W. M. Troetel, and B. P. Imbimbo. Effect of food on the absorption of eptastigmine. Eur. J. Clin. Pharmacol. 54:243–247 (1998).PubMedGoogle Scholar

  • 55.

    M. Stoltz, T. Arumugham, C. Lippert, D. Yu, V. Bhargava, M. Eller, and S. Weir. Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16 455A). Biopharm. Drug Dispos. 18:645–648 (1997).PubMedGoogle Scholar

  • 56.

    F. Ingels, B. Beck, M. Oth, and P. Augustijns. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers. Int. J. Pharm. 274:221–232 (2004).PubMedGoogle Scholar

  • 57.

    T. Shibuta, N. Inotsume, R. Iwaoku, and M. Nakano. Influence of food on pharmacokinetics and pharmacodynamics of furosemide. Byoin Yakugaku 14:12–16 (1988).Google Scholar

  • 58.

    H. A. Semple, Y. K. Tam, and R. T. Coutts. Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model. Pharm. Res. 7:274–279 (1990).PubMedGoogle Scholar

  • 59.

    L. X. Yu, A. B. Straughn, P. J. Faustino, Y. Yang, A. Parekh, A. B. Ciavarella, E. Asafu-Adjaye, M. U. Mehta, D. P. Conner, L. J. Lesko, and A. S. Hussain. The effect of food on the relative bioavailability of rapidly dissolving immediate-release solid oral products containing highly soluble drugs. Molecular Pharmaceutics 1:357–362 (2004).PubMedGoogle Scholar

  • 60.

    T. Kosoglou, D. J. Kazierad, J. J. Schentag, J. E. Patrick, L. Heimark, E. Radwanski, D. Christopher, B. E. Flannery, and M. B. Affrime. Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet. J. Clin. Pharmacol. 35:151–158 (1995).PubMedGoogle Scholar

  • 61.

    K. H. P. Moore, S. Shaw, A. L. Laurent, P. Lloyd, B. Duncan, D. M. Morris, M. J. O’Mara, and G. E. Pakes. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J. Clin. Pharmacol. 39:593–605 (1999).PubMedGoogle Scholar

  • 62.

    W. D. Hooper, R. G. Dickinson, and M. J. Eadie. Effect of food on absorption of lomefloxacin. Antimicrob. Agents Chemother. 34:1797–1799 (1990).PubMedGoogle Scholar

  • 63.

    D. A. Volpe. Permeability classification of representative fluoroquinolones by a cell culture method. AAPS PharmSci 6: e13 (2004).Google Scholar

  • 64.

    U. Busch, G. Heinzel, and H. Narjes. Effect of food on pharmacokinetics of meloxicam, a new nonsteroidal anti-inflammatory drug (NSAID). Agents Actions 32:52–53 (1991).PubMedGoogle Scholar

  • 65.

    G. Ranaldi, K. Islam, and Y. Sambuy. Epithelial cells in culture as a model for the intestinal transport of antimicrobial agents. Antimicrob. Agents Chemother. 36:1374–1381 (1992).PubMedGoogle Scholar

  • 66.

    N. B. Modi, B. Wang, W. T. Hu, and S. K. Gupta. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm. Drug Dispos. 21:23–31 (2000).PubMedGoogle Scholar

  • 67.

    J. Bass, K. V. Shepard, J. W. Lee, and J. Hulse. An evaluation of the effect of food on the oral bioavailability of sustained-release morphine sulfate tablets (ORAMORPH SR) after multiple doses. J. Clin. Pharmacol. 32:1003–1007 (1992).PubMedGoogle Scholar

  • 68.

    J. Lettieri, R. Vargas, V. Agarwal, and P. Liu. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400 mg in healthy male volunteers. Clin. Pharmacokinet. 40:19–25 (2001).PubMedGoogle Scholar

  • 69.

    M. N. Dudley, C. R. Marchbanks, S. C. Flor, and B. Beals. The effect of food or milk on the absorption kinetics of ofloxacin. Eur. J. Clin. Pharmacol. 41:569–571 (1991).PubMedGoogle Scholar

  • 70.

    L. D’Angelo, F. De Ponti, F. Crema, M. Caravaggi, and A. Crema. Effect of food on the bioavailability of pidotimod in healthy volunteers. Arzneim.-Forsch. 44:1473–1475 (1994).Google Scholar

  • 71.

    H. Y. Pan, A. R. DeVault, D. Brescia, D. A. Willard, M. E. McGovern, D. B. Whigan, and E. Ivashkiv. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int. J. Clin. Pharmacol., Ther., Toxicol. 31:291–294 (1993).Google Scholar

  • 72.

    M. A. H. Levine, S. E. Walker, and T. W. Paton. The effect of food and sucralfate on the bioavailability of S(+) and R(−) enantiomers of ibuprofen. J. Clin. Pharmacol. 32:1110–1114 (1992).PubMedGoogle Scholar

  • 73.

    F. Faassen, G. Vogel, H. Spanings, and H. Vromans. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int. J. Pharm. 263:113–122 (2003).PubMedGoogle Scholar

  • 74.

    L. I. Harrison, D. J. Riedel, K. E. Armstrong, M. B. Goldlust, and B. P. Ekholm. Effect of food on salsalate absorption. Ther. Drug Monit. 14:87–91 (1992).PubMedGoogle Scholar

  • 75.

    G. R. Granneman and D. Mukherjee. The effect of food on the bioavailability of temafloxacin. A review of 3 studies. Clin. Pharmacokinet. 22:48–56 (1992).PubMedCrossRefGoogle Scholar

  • 76.

    D. R. Doose, S. A. Walker, L. G. Gisclon, and R. K. Nayak. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J. Clin. Pharmacol. 36:884–891 (1996).PubMedGoogle Scholar

  • 77.

    D. Riendeau, M. D. Percival, C. Brideau, S. Charleson, D. Dube, D. Ethier, J. P. Falgueyret, R. W. Friesen, R. Gordon, G. Greig, J. Guay, J. Mancini, M. Ouellet, E. Wong, L. Xu, S. Boyce, D. Visco, Y. Girard, P. Prasit, R. Zamboni, I. W. Rodger, M. Gresser, A. W. Ford-Hutchinson, R. N. Young, and C. C. Chan. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 296:558–566 (2001).PubMedGoogle Scholar

  • 78.

    M. Hashiguchi, H. Ogata, A. Maeda, Y. Hirashima, S. Ishii, Y. Mori, T. Amamoto, T. Handa, N. Otsuka, et al. No effect of high-protein food on the stereoselective bioavailability and pharmacokinetics of verapamil. J. Clin. Pharmacol. 36:1022–1028 (1996).PubMedGoogle Scholar

  • 79.

    L. A. Nazareno, A. A. Holazo, R. Limjuco, S. Passe, S. K. Twardy, B. Min, and J. W. Massarella. The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients. Pharm. Res. 12:1462–1465 (1995).PubMedGoogle Scholar

  • 80.

    E. J. Seaber, R. W. Peck, D. A. Smith, J. Allanson, N. R. Hefting, J. J. Van Lier, F. A. E. Sollie, J. Wemer, and J. H. G. Jonkman. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Br. J. Clin. Pharmacol. 46:433–439 (1998).PubMedGoogle Scholar

  • 81.

    J. D. Irvine, L. Takahashi, K. Lockhart, J. Cheong, J. W. Tolan, H. E. Selick, and J. R. Grove. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88:28–33 (1999).PubMedGoogle Scholar

  • 82.

    M. V. S. Varma, K. Sateesh, and R. Panchagnula. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Molecular Pharmaceutics 2:12–21 (2005).PubMedGoogle Scholar

  • 83.

    G. E. Chittick, C. Gillotin, J. A. McDowell, Y. Lou, K. D. Edwards, W. T. Prince, and D. S. Stein. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy 19:932–942 (1999).PubMedGoogle Scholar

  • 84.

    G. Merino, A. I. Alvarez, J. G. Prieto, and R. B. Kim. The anthelmintic agent albendazole does not interact with P-glycoprotein. Drug Metab. Dispos. 30:365–369 (2002).PubMedGoogle Scholar

  • 85.

    X. Meng, P. Mojaverian, M. Doedee, E. Lin, I. Weinryb, S. T. Chiang, and P. R. Kowey. Bioavailability of amiodarone tablets administered with and without food in healthy subjects. cAm. J. Cardiol. 87:432–435 (2001).PubMedGoogle Scholar

  • 86.

    R. Dixon, A. L. Pozniak, H. M. Watt, P. Rolan, and J. Posner. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob. Agents Chemother. 40:556–560 (1996).PubMedGoogle Scholar

  • 87.

    H. Emori, S. Yokohama, and T. Nishihata. Small intestinal absorption of bropirimine in rats and effect of bile salt on the absorption. J. Pharm. Pharmacol. 47:487–492 (1995).PubMedGoogle Scholar

  • 88.

    H. Emori, K. Yamamoto, S. Yokohama, and T. Nishihata. Bioavailability of bropirimine 250 mg tablet in dogs: effect of food. J. Pharm. Pharmacol. 47:822–826 (1995).PubMedGoogle Scholar

  • 89.

    H. Saitoh, B. J. Aungst, M. Tohyama, Y. Hatakeyama, K. Ohwada, M. Kobayashi, H. Fujisaki, and K. Miyazaki. In vitro permeation of b-lactam antibiotics across rat jejunum and its correlation with oral bioavailability in humans. Br. J. Clin. Pharmacol. 54:445–448 (2002).PubMedGoogle Scholar

  • 90.

    S. K. Paulson, M. B. Vaughn, S. M. Jessen, Y. Lawal, C. J. Gresk, B. Yan, T. J. Maziasz, C. S. Cook, and A. Karim. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J. Pharmacol. Exp. Ther. 297:638–645 (2001).PubMedGoogle Scholar

  • 91.

    J. McEwen, G. Strauch, P. Perles, G. Pritchard, T. E. Moreland, J. Necciari, and J. P. Dickinson. Clopidogrel bioavailability: absence of influence of food or antacids. Semin. Thromb. Hemost. 25:47–50 (1999).PubMedGoogle Scholar

  • 92.

    A. Nordqvist, J. Nilsson, T. Lindmark, A. Eriksson, P. Garberg, and M. Kihlen. A general model for prediction of Caco-2 cell permeability. QSAR & Combinatorial Science 23:303–310 (2004).Google Scholar

  • 93.

    D. G. Blanchett, J. A. Green, A. Nara, R. Pospisil, R. C. Jarvis, R. J. Kasmer, D. A. Boyle, M. J. Cyronak, and C. N. Corder. The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure. Clin. Pharmacol. Ther. 49:449–456 (1991).PubMedCrossRefGoogle Scholar

  • 94.

    A. Clancy, J. Locke-Haydon, R. J. Cregeen, M. Ireson, and J. Ziemniak. Effect of concomitant food intake on absorption kinetics of fenoldopam (SK&F 82526) in healthy volunteers. Eur. J. Clin. Pharmacol. 32:103–106 (1987).PubMedGoogle Scholar

  • 95.

    J. Lavelle, S. Follansbee, C. B. Trapnell, W. C. Buhles, K. G. Griffy, D. Jung, A. Dorr, and J. Connor. Effect of food on the relative bioavailability of oral ganciclovir. J. Clin. Pharmacol. 36:238–241 (1996).PubMedGoogle Scholar

  • 96.

    K. A. Milton, G. Edwards, S. A. Ward, M. L. E. Orme, and A. M. Breckenridge. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br. J. Clin. Pharmacol. 28:71–77 (1989).PubMedGoogle Scholar

  • 97.

    R. L. Williams, J. Mordenti, R. A. Upton, E. T. Lin, W. L. Gee, C. D. Blume, and L. Z. Benet. Effects of formulation and food on the absorption of hydrochlorothiazide and triamterene or amiloride from combination diuretic products. Pharm. Res. 4:348–352 (1987).PubMedGoogle Scholar

  • 98.

    I. Soria, P. Myhre, V. Horton, P. Ellefson, S. McCarville, K. Schmitt, and M. Owens. Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose. Int. J. Clin. Pharmacol. Ther. 38:476–481 (2000).PubMedGoogle Scholar

  • 99.

    P. J. D. Kuang, C. Yeh, H. Haddix, M. Hesney, V. Hoagland, W. D. Ju, S. J. Justice, B. Osborne, A. T. Sterrett, J. A. Stone, E. Woolf, and S. Waldman. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob. Agents Chemother. 42:1308 (1998).Google Scholar

  • 100.

    N. N. Vachharajani, W. C. Shyu, D. S. Greene, and H. D. Uderman. Effects of food on the pharmacokinetics of irbesartan/hydrochlorothiazide combination tablet. Clin. Drug Investig. 16:399–404 (1998).Google Scholar

  • 101.

    A. Avdeef, P. E. Nielsen, and O. Tsinman. PAMPA—a drug absorption in vitro model 11. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates. Eur. J. Pharm. Sci. 22:365–374 (2004).PubMedGoogle Scholar

  • 102.

    D. Rosillon, A. Stockis, G. Poli, D. Acerbi, R. Lins, and B. Jeanbaptiste. Food effect on the oral bioavailability of Manidipine: single dose, randomized, crossover study in healthy male subjects. Eur. J. Drug Metab. Pharmacokinet. 23:197–202 (1998).PubMedCrossRefGoogle Scholar

  • 103.

    C. Crevoisier, J. Handschin, J. Barre, D. Roumenov, and C. Kleinbloesem. Food increases the bioavailability of mefloquine. Eur. J. Clin. Pharmacol. 53:135–139 (1997).PubMedGoogle Scholar

  • 104.

    A. Karim, L. F. Rozek, M. E. Smith, and K. G. Kowalski. Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog. J. Clin. Pharmacol. 29:439–443 (1989).PubMedGoogle Scholar

  • 105.

    D. S. Greene and R. H. Barbhaiya. Clinical pharmacokinetics of nefazodone. Clin. Pharmacokinet. 33: 260–275 (1997).Google Scholar

  • 106.

    S. M. Abdel-Rahman and G. L. Kearns. Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution and effect of food. Antimicrob. Agents Chemother. 42:2706–2709 (1998).PubMedGoogle Scholar

  • 107.

    S. M. Abdel-Rahman and G. L. Kearns. Single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults. J. Clin. Pharmacol. 39:613–618 (1999).PubMedGoogle Scholar

  • 108.

    B. J. Aungst, N. H. Nguyen, J. P. Bulgarelli, and K. Oates-Lenz. The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharm. Res. 17:1175–1180 (2000).PubMedGoogle Scholar

  • 109.

    J. Alsenz and E. Haenel. Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis. Pharm. Res. 20:1961–1969 (2003).PubMedGoogle Scholar

  • 110.

    R. A. Ronfeld, K. D. Wilner, and B. A. Baris. Sertraline: chronopharmacokinetics and the effect of coadministration with food. Clin. Pharmacokinet. 32:50–55 (1997).PubMedGoogle Scholar

  • 111.

    J. Shah, A. Fratis, D. Ellis, S. Murakami, and P. Teitelbaum. Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. J. Clin. Pharmacol. 30:733–736 (1990).PubMedGoogle Scholar

  • 112.

    J. B. Lecaillon, J. Godbillon, J. Campestrini, C. Naquira, L. Miranda, R. Pacheco, R. Mull, and A. A. Poltera. Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br. J. Clin. Pharmacol. 45:601–604 (1998).PubMedGoogle Scholar

  • 113.

    B. A. Hamelin, S. Allard, L. Laplante, J. Miceli, K. D. Wilner, J. Tremblay, and M. LeBel. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy 18:9–15 (1998).PubMedGoogle Scholar


Source: https://rd.springer.com/article/10.1007%2Fs11095-007-9236-1


BUY NOW For Sale 70%!
buy viagra

Clinical Exercise Electrocardiography - Page 375 - Google Books Result Cipro form cor 39

Tannosynt bad dosierung ciprofloxacin CALCIUM : Uses, Side Effects, Interactions and Warnings - WebMD
Tannosynt bad dosierung ciprofloxacin Biofilm Busting Protocol: H. pylori, Lyme, Gram
Tannosynt bad dosierung ciprofloxacin Cipro nursing implications - Ciprofloxacin msds sigma - Is ciprodex
Tannosynt bad dosierung ciprofloxacin Zymafluor d 500 beipackzettel ciprofloxacin
Tannosynt bad dosierung ciprofloxacin Cerco Socio - Ricerca i soci giusti per aprire un'attivit
Auro-Ciprofloxacin (ciprofloxacin) - Information. - Uniprix Ovarian Cancer: Symptoms, Signs, Treatment Survival Ciprofloxacin Injection: Indications, Side Effects Generic Medication: AMOXICILLINBROMHEXINE - Online Lasix 250 mg tropfen : Cipro 1a pharma 250 mg preis
BUY NOW For Sale 70%!
buy viagra